DK1479691T3 - Langvarigt aktive fuionspeptidinhibitorer for HIV infektion - Google Patents

Langvarigt aktive fuionspeptidinhibitorer for HIV infektion

Info

Publication number
DK1479691T3
DK1479691T3 DK04015696T DK04015696T DK1479691T3 DK 1479691 T3 DK1479691 T3 DK 1479691T3 DK 04015696 T DK04015696 T DK 04015696T DK 04015696 T DK04015696 T DK 04015696T DK 1479691 T3 DK1479691 T3 DK 1479691T3
Authority
DK
Denmark
Prior art keywords
virus
fuion
acting
long
hiv infection
Prior art date
Application number
DK04015696T
Other languages
Danish (da)
English (en)
Inventor
Dominique P Bridon
Martin Robitaille
Dong Xie
Jun Liang
John Erickson
Grant A Krafft
Elena Afonina
Meyer Sandra De
Original Assignee
John Erickson
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Erickson, Conjuchem Biotechnologies Inc filed Critical John Erickson
Application granted granted Critical
Publication of DK1479691T3 publication Critical patent/DK1479691T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04015696T 2001-05-31 2002-05-31 Langvarigt aktive fuionspeptidinhibitorer for HIV infektion DK1479691T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31
PCT/CA2002/000806 WO2002096935A2 (en) 2001-05-31 2002-05-31 Long lasting fusion peptide inhibitors for hiv infection

Publications (1)

Publication Number Publication Date
DK1479691T3 true DK1479691T3 (da) 2007-03-12

Family

ID=23132509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04015696T DK1479691T3 (da) 2001-05-31 2002-05-31 Langvarigt aktive fuionspeptidinhibitorer for HIV infektion

Country Status (12)

Country Link
US (2) US7741453B2 (ja)
EP (1) EP1390399B1 (ja)
JP (2) JP4463545B2 (ja)
AT (3) ATE345353T1 (ja)
AU (1) AU2002302277A1 (ja)
CA (1) CA2448891A1 (ja)
DE (3) DE60216151T2 (ja)
DK (1) DK1479691T3 (ja)
ES (2) ES2242860T3 (ja)
HK (1) HK1071379A1 (ja)
PT (1) PT1479691E (ja)
WO (1) WO2002096935A2 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006100T2 (de) * 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
WO2000069902A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
PT1360202E (pt) * 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
JP4463545B2 (ja) 2001-05-31 2010-05-19 コンジュケム バイオテクノロジーズ インコーポレイテッド Ｈｉｖ感染に対する長時間持続する融合ペプチドインヒビター
WO2004085505A2 (en) * 2003-03-24 2004-10-07 Sequoia Pharmaceuticals, Inc. Long acting biologically active conjugates
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
SI1745078T1 (sl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Postopek za äśiĺ äśenje albumin konjugatov
AU2005240680A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
AU2008254767A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
KR102238317B1 (ko) 2012-05-17 2021-04-12 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE183515T1 (de) * 1992-07-20 1999-09-15 Univ Duke Zusammensetzungen die die hiv replikation inhibieren
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996005389A1 (en) 1994-08-15 1996-02-22 B-Level Corp. Auxiliary surface-forming member for construction elements
CA2220339C (en) * 1995-05-10 2009-10-13 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
DE69806066T2 (de) 1997-11-07 2003-02-06 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1028971A2 (en) 1997-11-07 2000-08-23 ConjuChem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
WO1999048536A2 (en) 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
ATE298796T1 (de) * 1998-10-13 2005-07-15 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU2604200A (en) 1999-01-08 2000-07-24 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
WO2000070665A2 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CA2499211A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
WO2000069902A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
JP4463545B2 (ja) 2001-05-31 2010-05-19 コンジュケム バイオテクノロジーズ インコーポレイテッド Ｈｉｖ感染に対する長時間持続する融合ペプチドインヒビター
BR0314657A (pt) 2002-09-24 2005-08-02 Dong Xie Inibidores de fusão de derivados de peptìdeo de infecção de hiv
MXPA05002851A (es) 2002-09-27 2005-09-08 Tanox Inc Composiciones sinergicas para la prevencion y el tratamiento del sindrome de inmunodeficiencia adquirida.
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
WO2005007831A2 (en) 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
SI1745078T1 (sl) 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Postopek za äśiĺ äśenje albumin konjugatov
AU2005240680A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
CA2634495A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
JP4463545B2 (ja) 2010-05-19
DE60216151D1 (de) 2006-12-28
US7741453B2 (en) 2010-06-22
HK1071379A1 (en) 2005-07-15
US20110166061A1 (en) 2011-07-07
WO2002096935A3 (en) 2003-10-02
JP2005500274A (ja) 2005-01-06
WO2002096935A2 (en) 2002-12-05
ATE345353T1 (de) 2006-12-15
EP1390399A2 (en) 2004-02-25
JP2008308506A (ja) 2008-12-25
DE60216151T2 (de) 2007-09-27
ES2277173T3 (es) 2007-07-01
ATE412667T1 (de) 2008-11-15
ES2242860T3 (es) 2005-11-16
EP1390399B1 (en) 2005-05-11
DE60204137D1 (de) 2005-06-16
DE60204137T2 (de) 2006-01-26
DE60229677D1 (de) 2008-12-11
AU2002302277A1 (en) 2002-12-09
US20050065075A1 (en) 2005-03-24
CA2448891A1 (en) 2002-12-05
ATE295370T1 (de) 2005-05-15
PT1479691E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
DK1479691T3 (da) Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
DE69738535D1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
EA200700243A1 (ru) Способы лечения гепатита с
DE602006015861D1 (de) Antivirale verbindungen
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
TW200733953A (en) Materials and methods for treating viral infections
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
WO2005007078A3 (en) Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars)
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
WO2007002172A3 (en) Hiv-1 protease inhibitors
EP1752469A3 (en) Long lasting fusion peptide inhibitors for HIV infection
DE602006016416D1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen
ATE375800T1 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
WO2004108128A1 (fr) Utilisation de bullatacine dans la fabrication de medicaments anti-sida